Business Context and Reporting Period
Alnylam Pharmaceuticals, Inc. filed this Form 8-K on May 14, 2010, reporting an event that occurred on May 11, 2010. The company, headquartered in Cambridge, Massachusetts, entered into a material definitive agreement regarding its primary facility.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or liquidity metrics. The primary financial impact disclosed is an increase in operating lease obligations of $8.9 million through 2016.
Material Changes
On May 11, 2010, Alnylam executed a Third Amendment to its lease with ARE-MA Region No. 28, LLC for the premises at 300 Third Street, Cambridge, Massachusetts. Key changes include:
- Expansion of leased space by approximately 34,000 square feet (the entire first floor).
- Total leased space at the location will increase to approximately 129,000 square feet.
- The Additional Space is scheduled for delivery on or after October 1, 2010.
- The lease term remains set to expire on September 30, 2016, with options for two successive five-year extensions.
Outlook, Risks, and Management Commentary
Management intends to sublease the Additional Space through 2011. The filing does not provide specific guidance on future financial performance, nor does it detail specific risks or contingencies beyond the standard obligations of the lease agreement.
Investor Verification Checklist
- Verify the delivery date of the Additional Space (on or after October 1, 2010) to confirm when lease obligations commence.
- Confirm the status of the intended sublease for the Additional Space through 2011.
- Review the total committed operating lease obligations of $8.9 million against the company's current cash position.
- Assess the impact of the expanded footprint on future operating expenses relative to the company's development pipeline.